Halozyme repays $250 million term loan and increases revolver

Chicago, Aug. 19 – Halozyme Therapeutics Inc. amended its credit agreement from May 24 on Thursday to increase the size of the revolver, according to an 8-K filing with the Securities and Exchange Commission.

The revolver is now $575 million, increased from $350 million.

The terms of the revolver are otherwise unchanged.

The company had also said that it would repay the term loan on the credit facility and all outstanding loans under the revolver portion with a portion of the proceeds from a new offering of convertible notes. The company affirmed that it made the repayments on Thursday.

Bank of America is the administrative agent.

Halozyme is a San Diego-based biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.